AU · rank #8 · 2026-10-23
PLSE
NASDAQ · $3.39B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.608 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | -$0.02 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) $199,937 across 1 unique buyers. | 3.000 |
| Analyst upside Consensus target $62.33 | +18.3% |
| Momentum acceleration 3-month minus 12-month momentum. | +23.55% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.83 |
| Gross margin TTM | +0.3% |
| 52w high | $58.90 |
| Market cap (USD) | $3.39B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Pulse Biosciences is a medical device company developing proprietary nanosecond pulsed-field ablation (nPFA) technology for soft-tissue, benign thyroid, and cardiac arrhythmia applications.
Rationale
The analyst upside signal is well-supported as 3 price target raises in 30 days and 100% revision agreement reflect concrete clinical execution, including reaching NANOPULSE-AF pivotal trial enrollment ahead of schedule and securing a Clayman Thyroid Center partnership.
Material risks
- 1Clinical or regulatory setbacks, including FDA delays or unfavorable safety/efficacy data from the pivotal NANOPULSE-AF cardiac trial.
- 2Severe commercial crowding and potential displacement by established pulsed-field ablation platforms from heavily funded competitors like Medtronic, Boston Scientific, and Biosense Webster.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.